A common worry when starting a peptide protocol is telling effects that are expected and passing from effects that need attention. Every compound has a side effect profile, and knowing what is typical removes some of the uncertainty.
This article covers side effects across the main peptide and hormone categories, from labels and clinical trials where they exist. Where only user reports exist, it says so rather than giving rates.
Understanding side effects in context
Side effects sit on a spectrum. At one end are effects that are expected, dose-related and self-limiting; at the other are effects that are atypical, out of proportion or getting worse, which may need evaluation.
For the drugs with trial data, the common side effects fit the first pattern. In STEP 1, nausea and diarrhea with semaglutide were typically transient and mild to moderate and subsided with time; in SURMOUNT-1, tirzepatide's gastrointestinal events were mostly mild to moderate and occurred primarily during dose escalation.34 For research peptides, there is not enough human data to say.
Where it has been measured, side effects rise with dose. In retatrutide's phase 2 trial, gastrointestinal events were dose-related and partially mitigated with a lower starting dose (2 mg vs 4 mg).5 That is the reasoning behind titration: starting low and stepping up, as the GLP-1 labels do every 4 weeks.12
GLP-1 agonists
GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide, liraglutide) have the best documented side effect profile here, from large trials. Gastrointestinal effects dominate. The figures below are from the Wegovy and Zepbound labels' pooled weight-management trials.12
| Effect | Wegovy 2.4 mg (placebo) | Zepbound 5-15 mg (placebo) | Pattern |
|---|---|---|---|
| Nausea | 44% (16%) | 25-29% (8%) | Mostly during escalation |
| Diarrhea | 30% (16%) | 19-23% (8%) | Mostly mild to moderate |
| Constipation | 24% (11%) | 11-17% (5%) | Gastrointestinal |
| Vomiting | 24% (6%) | 8-13% (2%) | Mostly during escalation |
| Injection site reaction | Not in Table 3 | 6-8% (2%) | At the site |
| Headache | 14% (10%) | Not sourced here | General |
| Fatigue | 11% (5%) | Not sourced here | General |
| Abdominal pain | 20% (10%) | 9-10% (5%) | Gastrointestinal |
The gastrointestinal effects follow from how these drugs work: GLP-1 slows gastrointestinal motility and gastric emptying.6 The Zepbound label says its delay of gastric emptying is largest after the first dose and diminishes over time.2
On the Wegovy label, nausea was the most common adverse reaction leading to discontinuation (1.8% vs 0.2% on placebo), and 6.8% stopped for any adverse reaction.1 The titration schedule, starting low and stepping up every 4 weeks, is designed around tolerability, and Wegovy's label allows delaying a step by 4 weeks.1
Commonly suggested approaches include smaller, more frequent meals; less high-fat and fried food; staying hydrated; eating slowly and stopping at the first sign of fullness; and not lying down straight after eating. These are common suggestions, not trial results.
Healing peptides (BPC-157, TB-500)
BPC-157 and TB-500 are among the most used peptides for healing and recovery. User reports describe them as mild, but there is little human data to measure that against.
Neither has a large human trial. A 2025 systematic review of BPC-157 found 36 studies, 35 of them preclinical, and no clinical safety data; preclinical safety studies showed no adverse effects across several organ systems.7 The FDA says compounded BPC-157 may pose a risk of immunogenicity for some routes and has only limited safety information, and that it has not identified any human exposure data for TB-500 (a thymosin beta-4 fragment).8 The effects below are user reports, with no rates.
BPC-157
- Mild nausea: reported by users; no trial rate exists.
- Dizziness: reported by users; no trial rate exists.
- Injection site reactions: minor redness, itching or warmth, the same responses seen with any injection.
- Mild headache: reported by users; no trial rate exists.
- Warmth or flushing: reported by users; no trial rate exists.
TB-500
- Mild fatigue: reported by users; no trial rate exists.
- Injection site discomfort: reported by users, sometimes linked to larger injection volumes.
- Head rush: reported by users; no trial rate exists.
- Mild nausea: reported by users; no trial rate exists.
User reports describe these peptides as well tolerated, but without human trials there is no measured rate of any effect, common or rare.78
GH secretagogues
Growth hormone secretagogues (ipamorelin, CJC-1295, GHRP-2, GHRP-6, MK-677) stimulate the body's own growth hormone release.912 Their side effects are largely those of raised GH and IGF-1, plus compound-specific effects. The table gives trial findings where they exist.
| Effect | Compounds | Evidence | Notes |
|---|---|---|---|
| Water retention / edema | MK-677 | Trial11 | Transient, mild lower-extremity edema among the most frequent effects in a 2-year trial |
| Numbness / tingling | GH peptides | User reports | Hands and fingers; no trial rate sourced |
| Increased appetite | MK-677 | Trial11 | The most frequent effect; subsided in a few months |
| Muscle pain | MK-677 | Trial11 | Transient and mild |
| Cortisol and prolactin rise | GHRP (hexapeptide) | Trial10 | About 2-fold, only at the highest dose tested; ipamorelin did not raise ACTH or cortisol in swine{c("raun")} |
| Blood sugar elevation | MK-677 | Trial11 | Fasting glucose up 0.3 mmol/L (5 mg/dL) on average; insulin sensitivity fell |
| Heart rate, vasodilation | CJC-1295 | FDA8 | Serious adverse events reported to FDA |
Water retention is widely reported with GH secretagogues. In a 2-year trial of MK-677 25 mg daily in healthy older adults, transient, mild lower-extremity edema was among the most frequent side effects.11
Numbness and tingling (paresthesia), mainly in the hands and fingers, is reported by users of GH peptides. No trial rate for these peptides was sourced for this page.
MK-677 is oral and taken daily. In the 2-year trial, it raised GH and IGF-I to young-adult levels without serious adverse effects; appetite increased (subsiding in a few months), fasting glucose rose 0.3 mmol/L on average, insulin sensitivity fell, and body weight rose 2.7 kg against 0.8 kg on placebo.11 Separately, the FDA notes a hip fracture trial of ibutamoren that was terminated early for a potential signal of congestive heart failure.8
Ipamorelin was described in its first pharmacology paper as the first GHRP-receptor agonist with selectivity for GH release similar to GHRH: in swine it did not release ACTH or cortisol above GHRH levels, even at doses more than 200-fold above its ED50, while GHRP-6 and GHRP-2 did.9 Those are animal findings. The FDA notes a published study reporting serious adverse events, including death, with ipamorelin.8
Testosterone
Testosterone (testosterone enanthate, testosterone cypionate and other esters) has the most characterised side effect profile here, with decades of clinical use. The labels list:1314
- Acne: listed among skin effects on the Depo-Testosterone label, alongside seborrhea and hirsutism.14
- Hair thinning: male pattern baldness is listed on the Depo-Testosterone label; DHT, one of testosterone's major active metabolites, is the androgen linked to it.1413
- Mood changes: irritability and hypomania are among reactions reported in men on the Depo-Testosterone label.14
- Hematocrit elevation: among the most common adverse reactions on the Xyosted label; 4.2% reached 55% or more within a year, and the label evaluates hematocrit about every 3 months.13
- Estradiol: estradiol is one of testosterone's major active metabolites, and gynecomastia is listed on the Depo-Testosterone label.1314
- Testicular atrophy and fertility: testosterone inhibits pituitary LH, and testicular atrophy, subfertility and infertility are among reported reactions; the Xyosted label warns of possible azoospermia.1413
- Injection site reactions: injection site bruising is among the most common reactions on the subcutaneous Xyosted label; with intramuscular oil injections, post-injection pain is commonly reported.13
The profile changes with dose: replacement aims at mid-normal levels, by the Endocrine Society guideline, and oligospermia on the Depo-Testosterone label is linked to high dosages.1514 The Xyosted label also carries a boxed warning for blood pressure increases.13
Other commonly used peptides
PT-141 (bremelanotide)
PT-141 (bremelanotide) is approved as Vyleesi, used as needed. On its label, nausea affected 40.0% of patients against 1.3% on placebo, flushing 20.3%, and headache 11.3%; nausea, flushing, injection site reactions, headache and vomiting were the most common reactions.16
NAD+ and glutathione
NAD+ and glutathione are given by subcutaneous injection or IV infusion in wellness settings. Injection-site stinging, flushing and mild nausea are reported by users; no trial or label source was opened for this page.
Cognitive peptides (semax, selank)
Semax and selank are used intranasally, with limited clinical data. The FDA says it has no, or limited, safety information for semax and lacks important information on selank's safety in humans.8 User reports mention nasal irritation and mild headache.
What warrants immediate attention
Some presentations are not the typical pattern and are for prompt professional evaluation. They are uncommon but worth recognising.
Severe allergic reaction signs: Difficulty breathing, facial or throat swelling, widespread hives or rash, rapid heartbeat, dizziness or feeling faint. These are rare but require immediate attention.
Significant injection site reactions: Spreading redness extending well beyond the injection site, increasing warmth and hardness over 24-48 hours (rather than improving), tracking red lines from the site, or development of a hot, firm lump that grows over time. Normal injection site redness improves within hours; worsening over days is not normal.
Persistent severe GI symptoms: severe nausea, vomiting or abdominal pain that does not settle, particularly with dehydration. The Zepbound label warns of severe gastrointestinal reactions and of acute kidney injury due to dehydration from them.2
Significant mood or cognitive changes: Pronounced depression, anxiety, confusion, or personality changes that are out of proportion to baseline and correlate temporally with compound use.
Worsening trajectory: Any effect that is getting worse over time rather than improving. The typical trajectory for expected side effects is initial prominence followed by adaptation and resolution. An effect that intensifies over days or weeks rather than diminishing warrants evaluation.
Tracking side effects
Memory is a poor tool for tracking side effects. Something new on a new compound feels bigger than it is, while slow patterns over days or weeks are easy to miss.
Consistent subjective marker tracking, logging how you feel each day across a few key dimensions, transforms vague impressions into data. Instead of "I think the nausea has been getting worse," the data shows whether nausea scores are actually trending up, stable, or (as is more often the case) trending down from a peak in the first few days.
Tracking reveals several patterns that are difficult to detect otherwise:
- Temporal patterns: Is the nausea worst on injection day and improving by day 3? Is the fatigue correlated with a specific compound's timing? These patterns become visible in logged data but are nearly impossible to detect from memory alone.
- Dose-response relationships: Did the side effect emerge or worsen after a dose increase? Did it improve after a dose reduction? Logged data with timestamps and dose records makes this clear.
- Adaptation trajectory: Is the effect actually improving over weeks, or does it just feel that way because today happened to be a good day? A trendline across 14+ days reveals the actual trajectory.
- Distinguishing compound effects from life noise: Sleep quality, energy, mood: these fluctuate for many reasons unrelated to peptide use. When tracked consistently, it becomes possible to distinguish compound-related changes from normal baseline variation. A bad night's sleep or stressful week can produce effects that are easily misattributed to a peptide.
A common pattern: mild nausea on days 2 to 4 of a new compound, gone by day 10, remembered only as "I felt sick on this peptide". Equally, a worsening trend can hide behind a few good days. Daily check-ins on a few markers give a record that memory does not.
Frequently asked questions
Are GLP-1 side effects permanent?
In the trials, the common gastrointestinal effects were mostly transient: in STEP 1, nausea and diarrhea were typically mild to moderate and subsided with time, and in SURMOUNT-1 gastrointestinal events occurred primarily during dose escalation.34 The labels also list less common but serious risks, which are separate from these.12
How do you reduce nausea on semaglutide?
The label's titration is the main lever: Wegovy starts at 0.25 mg and steps up every 4 weeks, with the option to delay a step by 4 weeks if a dose is not tolerated.1 Commonly suggested habits are smaller meals, less fatty food, hydration, eating slowly, and not lying down straight after eating; these are suggestions, not trial results.
Does BPC-157 have side effects?
Users report it as well tolerated, mentioning mild nausea, dizziness, injection site redness and headache. There is no human trial rate for any of these: a 2025 systematic review found no clinical safety data, and the FDA notes a possible immunogenicity risk and only limited safety information.78
Why do GH peptides cause water retention?
Fluid retention is linked to raised GH. In a 2-year MK-677 trial, transient, mild lower-extremity edema was one of the most frequent side effects.11 No mechanism source was opened for this page.
When should I be concerned about peptide side effects?
For the drugs with trial data, most side effects are mild, passing and dose-related. Signs for professional evaluation include severe allergic reactions (breathing difficulty, swelling, widespread rash), injection site reactions that worsen over days, severe GI symptoms that do not settle, significant mood or cognitive changes, and any effect that keeps getting worse. For research peptides there is too little human data to say what is typical.
References
- Novo Nordisk (DailyMed). Wegovy (semaglutide) label. 2026. dailymed.nlm.nih.gov
- Eli Lilly (DailyMed). Zepbound (tirzepatide) label. 2026. dailymed.nlm.nih.gov
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. pubmed.ncbi.nlm.nih.gov
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007. pubmed.ncbi.nlm.nih.gov
- Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. pubmed.ncbi.nlm.nih.gov
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). 2026. fda.gov
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. pubmed.ncbi.nlm.nih.gov
- Bowers CY et al. GH-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990. pubmed.ncbi.nlm.nih.gov
- Nass R et al. Effects of an oral ghrelin mimetic (MK-677) on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008. pubmed.ncbi.nlm.nih.gov
- Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov
- Antares Pharma (DailyMed). Xyosted (testosterone enanthate) injection label. 2026. dailymed.nlm.nih.gov
- Pharmacia & Upjohn (DailyMed). Depo-Testosterone (testosterone cypionate) injection label. 2026. dailymed.nlm.nih.gov
- Bhasin S et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018. pubmed.ncbi.nlm.nih.gov
- Cosette Pharmaceuticals (DailyMed). Vyleesi (bremelanotide) injection label. 2026. dailymed.nlm.nih.gov